Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)

Kristie A Blum,Sin-Ho Jung,Ian Barak,Eric D Hsi,Nina D Wagner-Johnston,Beth Christian,Jim Atkins,Bruce D Cheson,John P Leonard,Nancy L Bartlett

doi:10.1182/blood.v130.suppl_1.485.485

Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)

Kristie A Blum, Sin-Ho Jung + Show 8 more

https://doi.org/10.1182/blood.v130.suppl_1.485.485

Copy DOI

Journal: Blood	Publication Date: Jun 25, 2021
Citations: 1

Affiliation: Saint Louis Zoo, Washington University in St. Louis, Southeast Clinical Oncology Research Consortium, Duke University, Georgetown University, The Ohio State University, Cleveland Clinic, Cornell College

#Follicular Lymphoma International Prognostic Index #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)

Full Text